Droga Pani. Pani wyrażane z głębokim przekonaniem, lecz bez naukowego rozeznania poglądy nie są miarodajne. A zamiast podsuwać czytelnikom kolejne opinie publicystyczne zbudowane jedynie na przekonaniach róznych osób, lecz nie poparte żadną teorią ani wynikami doświadczalnymi, powinna Pani częściej sięgać do źródeł naukowych

Brain aluminum concentration has been found significantly higher in patients dying with dialysis encephalopathy than in uremic patients without this syndrome. Uremic boy with high brain aluminum concentration showed symptoms of severe encephalopathy after treatment with oral aluminum hydroxide.
[Nathan E, Pedersen SE; Acta Paediatr Scand 69 (6): 793 (1980)] PEER REVIEWED

Aluminum hydroxide mixture in common with other aluminum compounds is astringent and may cause nausea, vomiting, and constipation. Large doses can cause intestinal obstruction. Excessive doses, or even normal doses in patients with low-phosphate diets, may lead to phosphate depletion accompanied by increased resorption and urinary excretion of calcium with the risk of renal rickets in the young or osteomalacia in older patients. Increases in plasma concentrations of aluminum are a toxic hazard of aluminium hydroxide mixture given to patients with poor renal function, or to those on dialysis, and encephalopathy and dementia have occurred. Aluminum hydroxide
[Reynolds, J.E.F., Prasad, A.B. (eds.) Martindale-The Extra Pharmacopoeia. 28th ed. London: The Pharmaceutical Press, 1982., p. 72] PEER REVIEWED

An 8-month-old white boy was brought to the emergency department due to irritability and pain with movement. Upon examination, the infant was irritable, unable to bear weight, had palpable clavicular bony lesions, point tenderness of the hips, and poor head control. The infant had lost several developmental milestones over the past 4 months (eg, ability to roll over) and had decreased appetite and minimal weight gain. Skeletal survey revealed multiple rib fractures, osteoporosis, and Ricketts. Hypophosphatemia (2.3 mg/dL; normal 3.2-6.3) and an elevated serum aluminum level (14 microg/L, normal 0-9) were noted. Past medical history was positive for gastroesophageal reflux. He had been started on ranitidine and aluminum hydroxide (1/2 teaspoonful per 6-ounce bottle) at 2 months of age.
[Robinson RF et al; Ann Pharmacother 38 (2): 265-268 (2004)] PEER REVIEWED

“in the past, aluminum hydroxide was believed to be cleared quickly from the body”

Post-vaccination granulomas a well-known reaction due to aluminium adsorbed vaccines. ...3 cases of children who developed sc nodules at the site of a previous injection of Tetracoq*vaccine (tetanus, diphtheria, Bordetella pertussis, poliovirus) were reported. Histologically, the lesions were characterized by a necrotizing granulomatous reaction with eosinophilic crystalline material. This material stained positively with the solochrome cyanine stain and was pink-purple.This aluminium stain enabled diagnosis of post-immunization injection-site reaction due to aluminium.
[Bordet Al et al; Ann Pathol 21 (2): 149-152 (20010] PEER REVIEWED

Brain Pathol. 2004 Jan;14(1):109-10, 115.
July 2003: 62-year-old female with progressive muscular weakness.

Bornemann A, Bohl J, Schneider HM, Goebel HH, Schmidt PF, Gherardi RK.

Institute of Brain Research, Eberhard-Karls University, Tübingen, Germany.

The July 2003 Case of the Month (COM). A 62-year-old female patient experienced progressive muscular weakness over the last ten years, involving shoulder and pelvic girdle muscles, paraspinal and facial muscles. A biopsy was taken from the left deltoid muscle where hepatitis vaccination had taken place 4 weeks previously. The specimen revealed macrophagic myofasciitis due to the injection of aluminium-bound vaccines. The finding can be reproduced experimentally by injecting vaccines in rats. The pathomechanism is supposed to involve immune stimulation due to long term persistence of the adjuvant. Macrophagic myofasciitis has been suggested to occasionally cause myopathy but is supposed to be unrelated to the underlying myopathy in our patient.

PMID: 14997943 [PubMed – indexed for MEDLINE]

Med Hypotheses. 2009 Feb;72(2):135-9. Epub 2008 Nov 11.
A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome.

Exley C, Swarbrick L, Gherardi RK, Authier FJ.

Birchall Centre for Inorganic Chemistry and Materials Science, Keele University, Staffordshire ST5 5BG, UK. c [dot] exley [at] chem [dot] keele [dot] ac [dot] uk

Macrophagic myofasciitis and chronic fatigue syndrome are severely disabling conditions which may be caused by adverse reactions to aluminium-containing adjuvants in vaccines. While a little is known of disease aetiology both conditions are characterised by an aberrant immune response, have a number of prominent symptoms in common and are coincident in many individuals. Herein, we have described a case of vaccine-associated chronic fatigue syndrome and macrophagic myofasciitis in an individual demonstrating aluminium overload. This is the first report linking the latter with either of these two conditions and the possibility is considered that the coincident aluminium overload contributed significantly to the severity of these conditions in this individual. This case has highlighted potential dangers associated with aluminium-containing adjuvants and we have elucidated a possible mechanism whereby vaccination involving aluminium-containing adjuvants could trigger the cascade of immunological events which are associated with autoimmune conditions including chronic fatigue syndrome and macrophagic myofasciitis.

PMID: 19004564 [PubMed – indexed for MEDLINE]